title: Enhancement of clara cell 10-kD protein (CC10) production from nasal epithelial cells by fexofenadine hydrochloride.
abstract: BACKGROUND
  Clara cell 10-kD protein (CC10) is well known to be an immuno-suppressive protein secreted from airway epithelial cells after inflammatory stimulation and is involved in the development of allergic disorders. Although histamine H1 receptor antagonists are used for the treatment of allergic disorders, the influence of the agents on CC10 production is not well understood. In the present study, we examined the influence of a histamine H1 receptor antagonist, fexofenadine hydrochloride (FEX) on CC10 production in vitro and in vivo.
  
  
  METHODS
  Nasal epithelial cells (5 x 10(6) cells/ml) were stimulated with 20 ng/ml TNF-alpha in the presence of various concentrations of FEX for 24 hours. CC10 levels in culture supernatants were examined by ELISA. Patients with Japanese cedar pollinosis were treated orally with FEX twice a day at a single dose of 60 mg for two weeks during Japanese cedar pollen season (February 2011 to April 2011). CC10 levels in nasal secretions were also examined by ELISA.
  
  
  RESULTS
  The addition of FEX into cell cultures caused increase in CC10 production induced by TNF-alpha stimulation, and the minimum concentration that caused significant increase was 200 ng/ml. Oral administration of FEX also increased CC10 levels in nasal secretions from pollinosis patients along with attenuation of clinical symptoms.
  
  
  CONCLUSIONS
  The ability of FEX to enhance CC10 production may account, at least in part, for the clinical efficacy of the agent in allergic disorders, including allergic rhinitis.
authors: Department of Otolaryngology, School of Medicine, Showa University, Tokyo, Japan.
authors: Taketoshi
authors: T
authors: Nogaki
authors: Kazuhito
authors: K
authors: Asano
authors: Atsuko
authors: A
authors: Furuta
authors: Ken-ichi
authors: K
authors: Kanai
authors: Isao
authors: I
authors: Suzaki
authors: Ayako
authors: A
authors: Kanei
authors: Harumi
authors: H
authors: Suzaki
mesh_terms: D000328:Adult; D002478:Cells, Cultured; D032485:Cryptomeria / Q000276:immunology; D004797:Enzyme-Linked Immunosorbent Assay; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D006634:Histamine H1 Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009296:Nasal Cavity / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D011058:Pollen / Q000276:immunology; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012720:Severity of Illness Index; D016593:Terfenadine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014598:Uteroglobin / Q000096:biosynthesis* / Q000276:immunology / Q000378:metabolism
chemical_list: D006634:Histamine H1 Antagonists; C556389:SCGB1A1 protein, human; D014409:Tumor Necrosis Factor-alpha; D016593:Terfenadine; D014598:Uteroglobin; C093230:fexofenadine